Alzheimer's drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal. Iacobucci G. BMJ 2026;392:s551.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Iacobucci G. Alzheimer's drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal. BMJ 2026;392:s551.
PMID: 41862174